GRDN vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GRDN presents a stark divergence between fundamental value and market price, with a Piotroski F-Score of 4/9 indicating only stable financial health. The stock is trading at a massive premium, with a current price of $37.93 compared to a Graham Number of $7.55 and an Intrinsic Value of $5.46. While growth metrics and analyst recommendations are strongly bullish, they are heavily offset by aggressive insider selling totaling over $419 million. The combination of extreme overvaluation and bearish insider sentiment outweighs the current growth trajectory.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GRDN vs LLY: Head-to-Head Comparison
This page compares Guardian Pharmacy Services, Inc. (GRDN) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.